Simon Kyaga
AuthID: R-00J-PP0
1
TÃTULO: Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials) (Nov, 10.1007/s10803-020-04709-8, 2020) Full Text
AUTORES: Crutel, V; Lambert, E; Penelaud, PF; Severo, CA; Fuentes, J; Rosier, A; Hervas, A; Marret, S; Oliveira, G; Parellada, M; Kyaga, S; Gouttefangeas, S; Bertrand, M; Ravel, D; Falissard, B;
PUBLICAÇÃO: 2021, FONTE: JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS
AUTORES: Crutel, V; Lambert, E; Penelaud, PF; Severo, CA; Fuentes, J; Rosier, A; Hervas, A; Marret, S; Oliveira, G; Parellada, M; Kyaga, S; Gouttefangeas, S; Bertrand, M; Ravel, D; Falissard, B;
PUBLICAÇÃO: 2021, FONTE: JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS
INDEXADO EM: 
WOS
WOS2
TÃTULO: Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials) Full Text
AUTORES: Veronique Crutel; Estelle Lambert; Pierre Francois Penelaud; Cristina Albarran Severo; Joaquin Fuentes; Antoine Rosier; Amaia Hervas; Stephane Marret; Guiomar Oliveira; Mara Parellada; Simon Kyaga; Sylvie Gouttefangeas; Marianne Bertrand; Denis Ravel; Bruno Falissard;
PUBLICAÇÃO: 2020, FONTE: JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS
AUTORES: Veronique Crutel; Estelle Lambert; Pierre Francois Penelaud; Cristina Albarran Severo; Joaquin Fuentes; Antoine Rosier; Amaia Hervas; Stephane Marret; Guiomar Oliveira; Mara Parellada; Simon Kyaga; Sylvie Gouttefangeas; Marianne Bertrand; Denis Ravel; Bruno Falissard;
PUBLICAÇÃO: 2020, FONTE: JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS
INDEXADO EM: 
Scopus WOS
Scopus WOS